Remi Barbier is founder, Chairman, and CEO of Pain Therapeutics, Inc., a firm developing novel drugs in the areas of pain management and oncology that he founded in 1998. Previously, Mr. Barbier helped in the founding and/or growth of: Exelixis Inc., a functional genomics company; ArQule, a chemistry company; and EnzyMed (now owned by Albany Molecular Research), a chemistry company. Mr. Barbier served as the Chief Operating Officer of Exelixis from January 1996 to May 1998. Mr. Barbier served as a Vice President of Corporate Development and Clinical Project Manager of Xoma Corporation, a biotechnology company from October 1993 to December 1995. Mr. Barbier serves as a Director of Mendel Biotechnology, Inc. and of Poetic Genetics, Inc.  He holds a BA from Oberlin College and an MBA from the University of Chicago. He is a trustee of the Carnegie Institute of Washington, the Santa Fe Institute, and on the Advisory Board of the California Institute for Quantitative Biosciences.